Pain Management

Migraine Patch Product No Longer Available

By October 20, 2017

Zecuity, launched in September 2015, is a transdermal system that delivers a therapeutic dose via a single-use, battery-powered patch wrapped around the upper arm or thigh.

Non-Opioid Tx Beats Hydromorphone for Migraine Pain Relief in the ED

By October 19, 2017

Participants were randomized to either hydromorphone 1mg (n=64) or prochlorperazine 10mg plus diphenhydramine 25mg (n=62).

Opioid Dependence Prevention Txs Compared in Head-to-Head Study

By October 18, 2017

Results found that all primary endpoints for non-inferiority of extended-release naltrexone group were met; retention in treatment (P=0.04), group proportion of total number of opioid-negative urine drug tests (P<0.001), days of heroin use (P<0.001) and days of other illicit opioids use (P<0.001).

BLA Submitted for Migraine Prevention Drug Fremanezumab

By October 17, 2017

The studies looked at the safety, tolerability, and efficacy of 4 dose regimens of subcutaneous fremanezumab vs. placebo over 16 weeks.

Intrahepatic Cholestasis Following Regular Consumption of Herbal Tea

By October 17, 2017

The case involved a 30-year-old female with a history of anxiety and migraine who presented with complaints of malaise, right upper quadrant pain, worsening jaundice, dark colored urine, and itching; these symptoms had been going on for a few weeks.

Diphenhydramine Improves Procedural Sedation Quality for Chronic Opioid Users

October 17, 2017

Researchers conducted a randomized, double-blind study involving patients using chronic opioids who were scheduled to undergo colonoscopy.

FDA Approves Treatment for Two Neuropathic Pain Conditions

By October 12, 2017

The efficacy of Lyrica CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.

Changing Marijuana Laws May Mean More Screening, Counseling Needed

October 10, 2017

In the changing legal environment, pediatric physicians must review their approach to screening for marijuana use and discussing the associated health consequences

Gabapentin, Opioid Combo May Up the Risk of Opioid-Related Death

By October 03, 2017

Both gabapentin and opioids are commonly prescribed for the treatment of pain.

Study Identifies Optimal Initial Opioid Rx Duration Following Surgery

September 28, 2017

Optimal length for each procedure lies between observed median prescription length and early nadir

New Type of Chronic Daily Headache Described in Case Series

By September 26, 2017

With regards to treatment, all of the patients responded to CSF pressure-/volume-lowering therapies (ie, acetazolamide or spironolactone).

FDA, Interpol Crack Down on Websites Selling Illegal Drugs

By September 25, 2017

In a statement the FDA said that products on sites they identified during the operation may be counterfeit, contaminated, expired or otherwise unsafe.

CVS Plans to Limit Opioid Rxs to 7-Day Supply for Certain Patients

By September 22, 2017

At the pharmacy level, a greater emphasis will be placed on counseling to help patients understand the risks associated with opioid use based on the new Centers for Disease Control and Prevention (CDC) guidelines.

FDA Clears Cefaly Device for Use During Migraine Attack

By September 21, 2017

Cefaly Acute is an external trigeminal nerve stimulator (e-TNS) approved for use under prescription.

Concomitant Naloxegol Tx Evaluated for Opioid Dose Impact

September 21, 2017

The researchers found that the mean daily numerical rating scale average pain scores varied from 4.5 to 4.8 for all groups in the 652 participants in KODIAC-04, and were 4.6 for each group of the 700 participants in KODIAC-05.

FDA: MAT Should Not Be Withheld from Patients on CNS Depressants

By September 20, 2017

"the dangers associated with failing to treat an opioid use disorder can outweigh the risks of co-prescribing MAT and benzodiazepines," said FDA Commissioner Scott Gottlieb.

Opioid, Unintentional Injury Deaths Contribute to Life Expectancy Decline

September 20, 2017

The researchers observed an increase in life expectancy at birth from 2000 to 2015, from 76.8 to 78.8 years.

Intellis SC Stimulator Approved for Chronic Pain

By September 18, 2017

The Intellis platform records and monitors patient activity 24/7, which can be accessed by physicians to track and make treatment adjustments as needed.

Teens Given Opioid Rx After Surgery More Likely to Be Persistent Users

By September 15, 2017

Results showed that new persistent opioid use, defined as continued opioid prescription fills between 90 and 180 days after the index surgical procedure, were 4.8% compared to 0.1% in the non-procedure control group.

AAP: ER Visits for Kids Testing Positive for Opioids on the Rise

September 15, 2017

ER visits for opioid dependence/abuse increased from 32,235 in 2008 to 49,626 in 2013

Investigational Migraine Tx Shows Promise in Phase 3 Trial

By September 14, 2017

Results demonstrated that at 12 weeks after the first dose of fremanezumab, the CM group had reductions of monthly headaches; -4.6 days for the monthly dose, -4.3 days for the quarterly dose and -2.5 for the placebo group (P<0.0001).

Oxygen Tx for Cluster Headache 'Not Prohibitively Expensive', Study Says

By September 14, 2017

The study concluded that the cost of medical grade oxygen for the acute treatment of CH is not prohibitively expensive for patients or for insurance providers.

Neuropathic Pain in Rheumatoid Arthritis Linked to Vitamin D Deficiency

September 13, 2017

Among patients with serum vitamin D levels <20 ng/mL, the prevalence of NP was 5.8 times higher than in patients with vitamin D levels ≥30 ng/mL.

Does Alcohol Consumption Increase the Risk of Migraine Attack?

By September 11, 2017

Of the total migraine sufferers, alcohol was deemed a risk factor for 64% of them.

Cardiovascular Study Supports Safety of Novel Migraine Tx Erenumab

By September 11, 2017

Results showed that at the end of the 12-week trial participants in the Aimovig 140mg group had a reduction of 7 MMDs and the 70mg group had a reduction of 5.4 days, while the placebo group had a reduction of 2.7 days (P<0.001).

Device for Migraine Prevention and Treatment Gets FDA Clearance

By September 07, 2017

The non-invasive SpringTMS device is placed at the back of the patient's head where a forced magnetic pulse is delivered to treat an acute attack or to prevent a future migraine onset.

Durolane Approved to Treat Knee Osteoarthritis Pain

By September 05, 2017

In clinical trials, treatment with Durolane effectively relieved pain and restored function for up to six months in patients with knee osteoarthritis.

AAOMS: Prescribing Recommendations for Acute and Post-Op Pain

By August 29, 2017

n the AAOMS White Paper, the Association urges prescribing ibuprofen over opioids as first-line therapy to manage acute and post-op pain.

Increases in BP, Hypertension Incidence Linked to Certain NSAIDs

By August 28, 2017

The PRECISION-ABPM study included 444 patients (408 with osteoarthritis; 36 RA) who had evidence of, or were at increased risk for, coronary artery disease.

Migraine Drug Therapies Examined for Appropriateness

August 28, 2017

The study team found that of 2,860 Americans who visited the doctor for migraine relief, 15.2% were prescribed opioids.